Zokinvy FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 19, 2021.
FDA Approved: Yes (First approved November 20, 2020)
Brand name: Zokinvy
Generic name: lonafarnib
Dosage form: Capsules
Company: Eiger BioPharmaceuticals, Inc.
Treatment for: Progeria and Progeroid Laminopathies
Zokinvy (lonafarnib) is an oral farnesyltransferase inhibitor (FTI) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL).
Development Timeline for Zokinvy
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.